EZH2 inhibitors have demonstrated effectiveness in specific subtypes of pediatric AML overexpressing EZH2 [104], and in primary pediatric B-cell and T-cell ALL samples [105]. This evidence concerns the gene EZH2 and acute myeloid leukemia.